Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Long-Term Deferred Tax (2024 - 2025)

Fate Therapeutics' Long-Term Deferred Tax history spans 2 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 100.35% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 100.35%, while the annual FY2025 figure was $2.3 million, 100.35% up from the prior year.
  • Long-Term Deferred Tax reached $2.3 million in Q4 2025 per FATE's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $2.3 million in Q4 2025 to a low of $1.1 million in Q4 2024.